PD-L1 Expression and Intra-Tumoral CD8⁺ T Lymphocytes in Esophageal Carcinosarcoma

References

• Hamilton SR, Hamilton SR, Aaltonen LA, Gabbert HE, et al. Squamous cell carcinoma of the esophagus. In: Hamilton SR, Aaltonen LA, editors. Tumors of the digestive system. Lyon: IARC Press; 2000. p. 11–19.
   Google Scholar
• Madan AK, Long AE, Weldon CB, Jaffe BM. Esophageal carcinosarcoma. J Gastrointest Surg. 2001;5(4):414–417.
   PubMed Web of Science ®Google Scholar
• Wang J, Wei D, Fan J, Zhu X. Clinical analysis of 24 cases of esophageal carcinosarcoma. Zhonghua Zhong Liu Za Zhi. 2014;36(8):633–635.
   PubMedGoogle Scholar
• Chen PC, Chen QX, Ni XH, Zhou XM, Mao WM. Clinicopathological features and prognostic analysis of esophageal sarcomatoid carcinoma. Zhonghua Zhong Liu Za Zhi. 2012;34(4):287–290.
   PubMedGoogle Scholar
• Wang L, Lin Y, Long H, Liu H, Rao H, He Y, et al. Esophageal carcinosarcoma: a unique entity with better prognosis. Ann Surg Oncol. 2013;20(3):997–1004.
   PubMed Web of Science ®Google Scholar
• Sano A, Sakurai S, Kato H, Sakai M, Tanaka N, Inose T, et al. Clinicopathological and immunohistochemical characteristics of esophageal carcinosarcoma. Anticancer Res. 2009;29(8):3375–3380.
   PubMed Web of Science ®Google Scholar
• Cavallin F, Scarpa M, Alfieri R, et al. Esophageal carcinosarcoma: management and prognosis at a single Italian series. Anticancer Res. 2014;34(12):7455–7459.
   PubMed Web of Science ®Google Scholar
• Iyomasa S, Kato H, Tachimori Y, Watanabe H, Yamaguchi H, Itabashi M. Carcinosarcoma of the esophagus: a twenty-case study. Jpn J Clin Oncol. 1990;20(1):99–106.
   PubMed Web of Science ®Google Scholar
• Kuo C-J, Lin T-N, Lin C-J, Wu R-C, Chang H-K, Chu Y-Y, et al. Clinical manifestation of esophageal carcinosarcoma: a Taiwan experience. Dis Esophagus. 2010;23(2):122–127.
   PubMed Web of Science ®Google Scholar
• Yu Z, Cheng BC, Chang S, et al. Clinicopathological analysis of esophageal carcinosarcoma: a report of 22 cases. Zhonghua Wei Chang Wai Ke Za Zhi. 2008;11(3):235–237.
   PubMedGoogle Scholar
• Zhang BH, Yang WJ, Wang YG, Zhang HT. Clinical manifestation and prognosis of the surgical treatment of esophageal carcinosarcoma. Zhonghua Wai Ke Za Zhi. 2012;50(3):256–259.
   PubMedGoogle Scholar
• Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MGM, Xu ML, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013;19(13):3462–3473. doi:https://doi.org/10.1158/1078-0432.CCR-13-0855.
   PubMed Web of Science ®Google Scholar
• Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006;203(4):883–895.
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003;9(5):562–567.
   PubMed Web of Science ®Google Scholar
• Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19(7):813–824. doi:https://doi.org/10.1093/intimm/dxm057.
   PubMed Web of Science ®Google Scholar
• Philips GK, Atkins M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol. 2015;27(1):39–46.
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 2007;104(9):3360–3365.
   PubMed Web of Science ®Google Scholar
• Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007;13(7):2151–2157.
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res. 2013;1(1):54–63.
   PubMed Web of Science ®Google Scholar
• Zou LQ, Yang X, Li YD, Zhu ZF. Immune checkpoint inhibitors: a new era for esophageal cancer. Expert Rev Anticancer Ther. 2019;19(8):731–738. doi:https://doi.org/10.1080/14737140.2019.1654379.
   PubMed Web of Science ®Google Scholar
• Schott DS, Pizon M, Pachmann U, Pachmann K. Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors. Oncotarget. 2017;8(42):72755–72772. doi:https://doi.org/10.18632/oncotarget.20346.
   PubMedGoogle Scholar
• Morihiro T, Kuroda S, Kanaya N, Kakiuchi Y, Kubota T, Aoyama K, et al. PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer. Sci Rep. 2019;9(1):4633.
   PubMedGoogle Scholar
• Kloten V, Lampignano R, Krahn T, Schlange T. Circulating tumor cell PD-L1 expression as biomarker for therapeutic efficacy of immune checkpoint inhibition in NSCLC. Cells. 2019;8(8):809. doi:https://doi.org/10.3390/cells8080809.
   Web of Science ®Google Scholar
• Kollmann D, Ignatova D, Jedamzik J, Chang Y-T, Jomrich G, Baierl A, et al. PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma. Oncoimmunology. 2018;7(6):e1435226. doi:https://doi.org/10.1080/2162402X.2018.1435226.
   PubMed Web of Science ®Google Scholar
• Guo W, Zhang F, Shao F, Wang P, Li Z, Yang X, et al. PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma. Hum Pathol. 2019;84:291–298. doi:https://doi.org/10.1016/j.humpath.2018.09.014.
   PubMed Web of Science ®Google Scholar
• Sim JK, Chung SM, Choi JH, Oh JY, Lee SH, Kim JH, et al. Clinical and molecular characteristics of pulmonary sarcomatoid carcinoma. Korean J Intern Med. 2018;33(4):737–744.
   PubMed Web of Science ®Google Scholar
• Yang Z, Xu J, Li R, Gao Y, He J. PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy. J Cancer Res Clin Oncol. 2019;145(12):3055–3065. doi:https://doi.org/10.1007/s00432-019-03023-w.
   PubMed Web of Science ®Google Scholar
• Zheng C, You W, Wan P, Jiang X, Chen J, Zheng Y, et al. Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: a systematic review and meta-analysis. Medicine. 2018;97(25):e11004. doi:https://doi.org/10.1097/MD.0000000000011004.
   PubMed Web of Science ®Google Scholar
• Ito S, Okano S, Morita M, Saeki H, Tsutsumi S, Tsukihara H, et al. Expression of PD-L1 and HLA class I in esophageal squamous cell carcinoma: prognostic factors for patient outcome. Ann Surg Oncol. 2016;23(Suppl 4):508–515. doi:https://doi.org/10.1245/s10434-016-5376-z.
   PubMedGoogle Scholar
• Loos M, Langer R, Schuster T, Gertler R, Walch A, Rauser S, et al. Clinical significance of the costimulatory molecule B7-H1 in Barrett carcinoma. Ann Thorac Surg. 2011;91(4):1025–1031. doi:https://doi.org/10.1016/j.athoracsur.2010.12.041.
   PubMed Web of Science ®Google Scholar
• Lequerica-Fernández P, Suárez-Canto J, Rodriguez-Santamarta T, Rodrigo JP, Suárez-Sánchez FJ, Blanco-Lorenzo V, et al. Prognostic relevance of CD4(+), CD8(+) and FOXP3(+) TILs in oral squamous cell carcinoma and correlations with PD-L1 and cancer stem cell markers. Biomedicines. 2021;9(6):653. doi:https://doi.org/10.3390/biomedicines9060653.
   PubMed Web of Science ®Google Scholar
• Wang G-Z, Zhang L, Zhao X-C, Gao S-H, Qu L-W, Yu H, et al. The aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy. Nat Commun. 2019;10(1):1125.
   PubMedGoogle Scholar
• Zhang H, Xia Y, Wang F, Luo M, Yang K, Liang S, et al. Aldehyde dehydrogenase 2 mediates alcohol-induced colorectal cancer immune escape through stabilizing PD-L1 expression. Adv Sci. 2021;8(10):2003404.
   Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancerScience. 2015;348(6230):124–128. doi:https://doi.org/10.1126/science.aaa1348.
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Ju YS, Haase K, Van Loo P, Martincorena I, Nik-Zainal S, et al. Mutational signatures associated with tobacco smoking in human cancer. Science. 2016;354(6312):618–622. doi:https://doi.org/10.1126/science.aag0299.
   PubMed Web of Science ®Google Scholar
• Svensson MC, Borg D, Zhang C, Hedner C, Nodin B, Uhlén M, et al. Expression of PD-L1 and PD-1 in chemoradiotherapy-naive esophageal and gastric adenocarcinoma: relationship with mismatch repair status and survival. Front Oncol. 2019;9:136.
   PubMed Web of Science ®Google Scholar
• Noh BJ, Kwak JY, Eom DW. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma. BMC Cancer. 2020;20(1):58.
   PubMed Web of Science ®Google Scholar
• Hodgson A, Vesprini D, Liu SK, Xu B, Downes MR. Correlation of mismatch repair protein deficiency, PD-L1 and CD8 expression in high-grade urothelial carcinoma of the bladder. J Clin Pathol. 2020;73(8):519–522.
   PubMed Web of Science ®Google Scholar
• Kunc M, Gabrych A, Rękawiecki B, Gorczyński A, Haybaeck J, Biernat W, et al. Immunohistochemical evaluation of mismatch repair proteins and p53 expression in extrauterine carcinosarcoma/sarcomatoid carcinoma. Contemp Oncol. 2020;24(1):1–4. doi:https://doi.org/10.5114/wo.2020.94718.
   Google Scholar